2023年ESMO基于分子指导的原发灶不明肿瘤治疗新进展

Progress in clinical management of cancer of unknown primary based on molecular testing at 2023 ESMO

原发灶不明肿瘤(cancer of unknown primary,CUP)是一类组织学上确定为转移并经过一系列检查仍未找到原发灶的肿瘤,占所有新发肿瘤的2%~5%。CUP具有侵袭性强、早期转移及预后差等特征。随着新兴基因检测和药物的应用,基因表达谱和基因组检测在揭示肿瘤分子特征中的价值日益凸显,基于分子指导的靶向治疗和免疫治疗等新的治疗选择也应运而生。本文就2023年欧洲肿瘤学会(European Society for Medical Oncology,ESMO)年会上报道的有关CUP的临床试验进行述评。

Cancer of unknown primary(CUP)is a metastatic syndrome with an unidentifiable primary tumor even after comprehensive clinical and pathological investigations,accounting for approximately 2%-5%of all newly diagnosed cancers.CUP has some common features including aggressiveness,early dissemination and poor prognosis.With the application of novel molecular tests and drugs,the diagnostic value of gene expression assay and genomic tests in characterizing the molecular features has become increasingly prominent,and new treatment options such as molecular-guided targeted therapy and immunotherapy have become available.This article reviewed the clinical trials of CUP reported at 2023 European Society for Medical Oncology(ESMO)Congress.